Literature DB >> 35194187

Human cytomegalovirus hijacks host stress response fueling replication stress and genome instability.

Joanna Maria Merchut-Maya1,2, Jiri Bartek16,17,18, Jirina Bartkova1,6, Panagiotis Galanos1, Mattia Russel Pantalone3,7, MyungHee Lee1,2, Huanhuan L Cui3, Patrick J Shilling8, Christian Beltoft Brøchner9, Helle Broholm9, Apolinar Maya-Mendoza10,11, Cecilia Söderberg-Naucler12,13,14,15, Jiri Bartek16,17,18.   

Abstract

Viral infections enhance cancer risk and threaten host genome integrity. Although human cytomegalovirus (HCMV) proteins have been detected in a wide spectrum of human malignancies and HCMV infections have been implicated in tumorigenesis, the underlying mechanisms remain poorly understood. Here, we employed a range of experimental approaches, including single-molecule DNA fiber analysis, and showed that infection by any of the four commonly used HCMV strains: AD169, Towne, TB40E or VR1814 induced replication stress (RS), as documented by host-cell replication fork asymmetry and formation of 53BP1 foci. The HCMV-evoked RS triggered an ensuing host DNA damage response (DDR) and chromosomal instability in both permissive and non-permissive human cells, the latter being particularly relevant in the context of tumorigenesis, as such cells can survive and proliferate after HCMV infection. The viral major immediate early enhancer and promoter (MIEP) that controls expression of the viral genes IE72 (IE-1) and IE86 (IE-2), contains transcription-factor binding sites shared by promoters of cellular stress-response genes. We found that DNA damaging insults, including those relevant for cancer therapy, enhanced IE72/86 expression. Thus, MIEP has been evolutionary shaped to exploit host DDR. Ectopically expressed IE72 and IE86 also induced RS and increased genomic instability. Of clinical relevance, we show that undergoing standard-of-care genotoxic radio-chemotherapy in patients with HCMV-positive glioblastomas correlated with elevated HCMV protein markers after tumor recurrence. Collectively, these results are consistent with our proposed concept of HCMV hijacking transcription-factor binding sites shared with host stress-response genes. We present a model to explain the potential oncomodulatory effects of HCMV infections through enhanced replication stress, subverted DNA damage response and induced genomic instability.
© 2022. The Author(s), under exclusive licence to ADMC Associazione Differenziamento e Morte Cellulare.

Entities:  

Mesh:

Year:  2022        PMID: 35194187      PMCID: PMC9346009          DOI: 10.1038/s41418-022-00953-w

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   12.067


  52 in total

1.  Survival in patients with glioblastoma receiving valganciclovir.

Authors:  Cecilia Söderberg-Nauclér; Afsar Rahbar; Giuseppe Stragliotto
Journal:  N Engl J Med       Date:  2013-09-05       Impact factor: 91.245

2.  Frequent occurrence of therapeutically reversible CMV-associated encephalopathy during radiotherapy of the brain.

Authors:  Nicole L Goerig; Benjamin Frey; Klaus Korn; Bernhard Fleckenstein; Klaus Überla; Manuel A Schmidt; Arnd Dörfler; Tobias Engelhorn; Ilker Eyüpoglu; Paul F Rühle; Florian Putz; Sabine Semrau; Udo S Gaipl; Rainer Fietkau
Journal:  Neuro Oncol       Date:  2016-06-10       Impact factor: 12.300

Review 3.  Update on treatment of cytomegalovirus infection in pregnancy and of the newborn with congenital cytomegalovirus.

Authors:  William D Rawlinson; Stuart T Hamilton; Wendy J van Zuylen
Journal:  Curr Opin Infect Dis       Date:  2016-12       Impact factor: 4.915

4.  Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma.

Authors:  Andrea Schuessler; Corey Smith; Leone Beagley; Glen M Boyle; Sweera Rehan; Katherine Matthews; Linda Jones; Tania Crough; Vijayendra Dasari; Kerenaftali Klein; Amy Smalley; Hamish Alexander; David G Walker; Rajiv Khanna
Journal:  Cancer Res       Date:  2014-05-04       Impact factor: 12.701

5.  Human cytomegalovirus US28 found in glioblastoma promotes an invasive and angiogenic phenotype.

Authors:  Liliana Soroceanu; Lisa Matlaf; Vladimir Bezrookove; Loui Harkins; Roxanne Martinez; Mary Greene; Patricia Soteropoulos; Charles S Cobbs
Journal:  Cancer Res       Date:  2011-09-07       Impact factor: 12.701

6.  Genetic analysis of cytomegalovirus in malignant gliomas.

Authors:  Bornali Bhattacharjee; Nicholas Renzette; Timothy F Kowalik
Journal:  J Virol       Date:  2012-04-11       Impact factor: 5.103

7.  Human cytomegalovirus and herpes simplex type 2 virus in normal and adenocarcinomatous prostate glands.

Authors:  I Boldogh; J F Baskar; E C Mar; E S Huang
Journal:  J Natl Cancer Inst       Date:  1983-05       Impact factor: 13.506

8.  Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis.

Authors:  Catherine de Martel; Damien Georges; Freddie Bray; Jacques Ferlay; Gary M Clifford
Journal:  Lancet Glob Health       Date:  2019-12-17       Impact factor: 26.763

9.  Human cytomegalovirus infection and expression in human malignant glioma.

Authors:  Charles S Cobbs; Lualhati Harkins; Minu Samanta; G Yancey Gillespie; Suman Bharara; Peter H King; L Burt Nabors; C Glenn Cobbs; William J Britt
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

10.  Detection of human cytomegalovirus in normal and neoplastic breast epithelium.

Authors:  Lualhati E Harkins; Lisa A Matlaf; Liliana Soroceanu; Katrin Klemm; William J Britt; Wenquan Wang; Kirby I Bland; Charles S Cobbs
Journal:  Herpesviridae       Date:  2010-12-23
View more
  2 in total

1.  Valganciclovir as Add-on to Second-Line Therapy in Patients with Recurrent Glioblastoma.

Authors:  Mattia Russel Pantalone; Afsar Rahbar; Cecilia Söderberg-Naucler; Giuseppe Stragliotto
Journal:  Cancers (Basel)       Date:  2022-04-13       Impact factor: 6.575

Review 2.  Cytomegalovirus and Glioblastoma: A Review of the Biological Associations and Therapeutic Strategies.

Authors:  Tianrui Yang; Delin Liu; Shiyuan Fang; Wenbin Ma; Yu Wang
Journal:  J Clin Med       Date:  2022-09-04       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.